Understand the source comparison
GHRP-2 Acetate: Peptide Comparison
Researchers selecting growth hormone secretagogues for experimental protocols frequently compare GHRP-2 acetate against structurally related peptides. The table below summarises key differentiators across receptor selectivity, secondary endocrine effects, and
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers selecting growth hormone secretagogues for experimental protocols frequently compare GHRP-2 acetate against structurally related peptides. The table below summarises key differentiators across receptor selectivity, secondary endocrine effects, and typical research applications.
- | Peptide | GHS-R1a Affinity | Appetite Stimulation | Prolactin/Cortisol Elevation | Typical Dosing Range (Rodent) | Research Application Focus | Professional Assessment ||—|—|—|—|—|—|| GHRP-2 Acetate | High (EC50 ~0.1 nM) | Low-Moderate | Minimal at ≤3 mcg/kg | 1–3 mcg/kg SC | GH secretion studies, metabolic research, lifespan studies | Ideal for protocols requiring GH-specific stimulus without appetite confounds || GHRP-6 | High (EC50 ~0.2 nM) | High | Minimal at ≤3 mcg/kg | 1–3 mcg/kg SC | Appetite regulation, cachexia models | Strong GH response but significant feeding behaviour. Limits metabolic interpretation || Ipamorelin | Moderate (EC50 ~1.3 nM) | None | None | 100–300 mcg/kg SC | Selective GH studies, aging research | Most selective for GH. No secondary endocrine effects but requires higher doses || Hexarelin | Very High (EC50 ~0.05 nM) | Moderate | Significant at >2 mcg/kg | 0.5–2 mcg/kg SC | Cardioprotection studies, GH receptor desensitisation models | Potent but rapid tac
- GRHP-2 acetate occupies a distinct niche. Comparable GH secretion potency to GHRP-6 with significantly lower appetite stimulation, making it the preferred choice for metabolic studies where feeding behaviour would confound energy expenditure or body composition outcomes. Unlike hexarelin, GHRP-2 demonstrates minimal receptor desensitisation over 14-day continuous administration protocols, maintaining 80–85% of initial GH response amplitude. This durability makes it suitable for sub-chronic experimental designs that ipamorelin and hexarelin cannot support.